Two BILLION people with untreated mental health disorders is a lot of market potential. We attach some numbers to these treatment markets.
TSI EDITOR |
2021-09-09
Psyched Wellness moves a step closer to commencing its Phase I clinical trial on AME-1. The company is still targeting commercialization for 2022.
TSI EDITOR |
2021-09-08
Red Light Holland closes on its majority ownership in Acadian Exotic Mushrooms, now holding a 51% interest.
TSI EDITOR |
2021-09-07
Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
TSI EDITOR |
2021-09-07
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
TSI EDITOR |
2021-09-07
The DEA fights to keep psychedelic drugs illegal while it admits these drugs have valuable medical uses. Meanwhile, Americans are dying every day from lack of legal access.
TSI EDITOR |
2021-09-02
MINDCURE reports a net loss for the fiscal year of CAD$10.2 million as it prepares to deploy its iSTRYM digital therapeutics platform. Cash and equivalents of CAD$18.3 million.
TSI EDITOR |
2021-09-01
Red Light Holland reports its Q1 for fiscal year 2022. The company also confirms closing on its acquisition of Mera Life Sciences.
TSI EDITOR |
2021-08-31
As investors look to fine-tune their portfolios after the summer, we review the psychedelic drug industry and public company performance in 2021.
TSI EDITOR |
2021-08-30
MINDCURE has released the initial version of its iSTRYM digital therapeutics platform and expects to begin full commercial deployment in Q1 of 2022.
TSI EDITOR |
2021-08-26
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now